WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation (NASDAQ:CERS) announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components. After sample platelet components were inoculated with XMRV, the infected blood components were treated with INTERCEPT, a system that inactivates pathogens in donated blood. Following treatment, no evidence of infectious XMRV was detected in blood samples. The study results have been submitted for presentation at the AABB Annual Meeting in October.

“Due to its leadership in the discovery and characterization of XMRV, WPI is an ideal partner to confirm the efficacy of our treatment process”

XMRV is a retrovirus that has recently been linked to prostate cancer and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Other retroviruses, such as HIV and HTLV-1, are known to cause cancer and immune deficiencies. Studies by WPI researchers and collaborators have confirmed that infectious XMRV can be found in human blood cells and that the virus is transmitted through body fluids.

In the joint study conducted by WPI and Cerus, blood samples were evaluated in a validated virus culture test, which allows sensitive detection of XMRV particles that are capable of reproducing. Cerus' INTERCEPT Blood System inactivates pathogens by crosslinking their DNA or RNA, thereby blocking replication and preventing subsequent transmission of infection. INTERCEPT has previously been demonstrated to inactivate high levels of both HIV and HTLV. Cerus and WPI decided to collaborate on inactivation studies for XMRV in order to characterize the treatment's efficacy against this newly recognized human retrovirus.

While research is ongoing regarding the prevalence and disease association of the virus, concern for potential transfusion transmission of XMRV has already led blood centers in Australia, Canada, the United Kingdom and New Zealand to ban donations from blood donors with ME/CFS. Earlier this month, the Chronic Fatigue Syndrome Advisory Committee of the U.S. Department of Health and Human Services voted unanimously to recommend that U.S. blood centers also defer donors with diagnosed ME/CFS.

"As XMRV is a human retrovirus like HIV, one immediately wonders about the possibility for transfusion transmission of XMRV," said Dr. Judy Mikovits, director of research at WPI. "We chose to work with Cerus on this joint study because developing prevention strategies for XMRV-linked neuro-immune diseases is an important element of the WPI's mission."

"Due to its leadership in the discovery and characterization of XMRV, WPI is an ideal partner to confirm the efficacy of our treatment process," added Lily Lin, vice president of global scientific affairs for Cerus. "Emerging pathogens such as XMRV are a particular challenge for blood transfusion services and highlight a weakness in the current blood banking system."

The INTERCEPT systems for platelets and plasma are used by over 40 blood centers in Europe, Russia and the Middle East. The INTERCEPT Blood System is not yet approved for use in the United States.